BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1060@pharmaconomics
DTSTAMP:20260707T034856Z
DTSTART;VALUE=DATE:20260602
DTEND;VALUE=DATE:20260603
SUMMARY:INMB Phase 2 — XPro1595
DESCRIPTION:Phase 2 trial results for XPro1595 in Alzheimer's disease are due Jun 2\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1711754/000121390026064144/ea029332501ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/1060
URL:https://www.pharmaconomics.com/e/1060
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:INMB catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR